Prof. Wu’s research interest includes clinical genetics, cognition, and pathogenesis of Parkinson’s disease and related disorders. She has established a long-term follow-up cohort of idiopathic and familial Parkinson’s disease in a hospital-based electronic case management system by a collection of more than 2500 index cases of PD and 800 healthy controls consisting of the detail clinical profiles, DNA and plasma samples. She has led her group to identify G2385R and R1628P of LRRK2 as the unique genetic risk factors in PD in Asian populations and reported anxiety, constipation, depression, and antihypertensive agents as risk factors in the development of PD in Taiwanese. Using the integrated approach of combining gene dosage analysis and next-generation sequencing, her group specified the clinical phenotypes and genetic causes in early-onset and familial PD in Taiwanese. Her group first found the hyperphosphorylation of HTRA2 protein in mitochondria contributing the neuronal death with HTRA2 gene mutation and discovered lovastatin protected neurite degeneration in LRRK2-G2019S parkinsonism through the activation of Akt/Nrf pathway and inhibition of GSK3β activity. Prof WU led the task force of Traditional Chinese translation of the MDS UPDRS and Dyskinesia rating scale, including the experts in Hong Kong and Taiwan, and verified the Cross-Cultural Differences of the Non-Motor Symptoms between Chinese and western population in PD. She is one of the members of the IPMDS Study Group for the “Validation of Mild Cognitive Impairment in Parkinson Disease” by detecting Mild Cognitive Deficits in PD in the Comparison of Neuropsychological Tests.